Artelo Biosciences (ARTL) Net Cash Flow Growth (1y) (2015 - 2025)
Artelo Biosciences (ARTL) Net Cash Flow Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 44.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.48% |
| Sep 30, 2025 | -108.76% |
| Jun 30, 2025 | 515.97% |
| Mar 31, 2025 | 1.30% |
| Dec 31, 2024 | -1,235.59% |
| Sep 30, 2024 | 212.04% |
| Jun 30, 2024 | 74.43% |
| Mar 31, 2024 | -12,546.15% |
| Dec 31, 2023 | 148.76% |
| Sep 30, 2023 | 35.11% |
| Jun 30, 2023 | -164.93% |
| Mar 31, 2023 | 100.72% |
| Nov 30, 2021 | 41.81% |
| Feb 28, 2021 | 336.29% |
| Nov 30, 2020 | 593.51% |
| Aug 31, 2020 | -79.72% |
| May 31, 2020 | -332.93% |
| Feb 29, 2020 | -504.87% |
| Nov 30, 2019 | -368.92% |
| Aug 31, 2019 | 34,472.16% |